Literature DB >> 9626457

Analysis of DNA mismatch repair proteins in human medulloblastoma.

S E Lee1, S P Johnson, L P Hale, J Li, N Bullock, H Fuchs, A Friedman, R McLendon, D D Bigner, P Modrich, H S Friedman.   

Abstract

During replication, the primary function of the eukaryotic DNA mismatch repair (MMR) system is to recognize and correct mismatched base pairs within the DNA helix. Deficiencies in MMR have been reported previously in cases of hereditary nonpolyposis colorectal cancer and sporadic tumors occurring in a variety of tissues including gliomas. Furthermore, recent evidence indicates that the MMR system may be involved in mediating therapeutic sensitivity to alkylating agents. In this study, 22 neoplastic tissue samples from 22 patients who underwent surgical resection for medulloblastoma, a common cerebellar tumor of childhood, were assayed for the presence or absence of MMR polypeptides using Western blot and immunohistochemical techniques. Results from these experiments indicate that the MMR system is not commonly deficient in medulloblastoma.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9626457

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  3 in total

1.  Analysis of microsatellite instability in medulloblastoma.

Authors:  Marta Viana-Pereira; Inês Almeida; Sónia Sousa; Bethânia Mahler-Araújo; Raquel Seruca; José Pimentel; Rui Manuel Reis
Journal:  Neuro Oncol       Date:  2009-01-29       Impact factor: 12.300

2.  Copper influx transporter 1 is required for FGF, PDGF and EGF-induced MAPK signaling.

Authors:  Cheng-Yu Tsai; J Cameron Finley; Sameh S Ali; Hemal H Patel; Stephen B Howell
Journal:  Biochem Pharmacol       Date:  2012-07-25       Impact factor: 5.858

3.  Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumours.

Authors:  A O von Bueren; M D Bacolod; C Hagel; K Heinimann; A Fedier; U Kordes; T Pietsch; J Koster; M A Grotzer; H S Friedman; G Marra; M Kool; S Rutkowski
Journal:  Br J Cancer       Date:  2012-09-13       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.